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M
ore than a decade after the National Research Council pushed for broad test-
ing of toxic substances in people and more than 40 years after the birth of
the ongoing National Health and Nutrition Examination Survey
(NHANES), data on human exposures to potential toxicants continue to come in.
The latest contribution came with the January 2003 release of the Second National
Report on Human Exposure to Environmental Chemicals by the Centers for Disease
Control and Prevention (CDC). The report presents findings on the presence of a
small selection of potentially toxic substances in a group of volunteer test subjects.
It more than quadrupled the number of substances covered in the CDC’s first
report released two years earlier, adding in new chemicals, congeners, and natural-
ly occurring substances. Already it is a useful tool for many organizations, physi-
cians, and agencies.
“The ability to have a database like this as a baseline reference is very powerful,”
says Paul Gilman, assistant administrator for research and development in the U.S.
Environmental Protection Agency (EPA) Office of Research and Development.
“This work puts things in a context for us.” 
The CDC findings revealed some significant reductions during the past decade
for some of the substances, such as lead and secondhand tobacco smoke. But the
findings also unveiled many puzzles, such as large variations in some of the con-
centrations measured by age, sex, and race/ethnicity, and differences of 200-fold or
more between concentrations found in the lowest and highest percentiles reported.
These puzzles highlighted one of the main points made by the CDC with the release
of the report—that much about human exposure remains a mystery, and that one
of the primary uses of the data will be to help shape future research. The CDC
report offered no new information on health effects from the measured exposures,
another field in which the CDC acknowledged much research is needed.
The CDC’s decisions on which substances to include in the Second National
Report were influenced by six considerations: data showing exposure to U.S. resi-
dents; known or suspected serious health effects from exposures; availability of good
analytical methods to evaluate a substance; testing costs; availability of adequate
blood or urine samples; and a desire to track selected public health interventions
over time. 
The 116 substances covered in the Second National Report are only the tip of
the iceberg as far as potential chemical exposures go. About 2,900 high produc-
tion volume chemicals—regularly produced or imported in volumes of 1 million
or more pounds per year—are among the chemicals under investigation by many
agencies and companies. There are at least 80,000 chemicals, with largely 
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Focus | Body of Evidenceunknown toxicity, that have ever been reg-
istered under the Toxic Substances Control
Act as being in commerce in the United
States (an estimated 20,000 more have
ever been in commerce elsewhere in the
world). There may be about 6 million
chemicals that exist in the world, says John
Osterloh, chief medical officer for the
CDC Environmental Health Laboratory,
although estimates vary and no one really
knows. Many of these are not produced for
commerce but rather exist as breakdown
and incineration products of chemicals
that are in commerce. The number of
these substances that may reside for any
length of time in people is a mystery. The
CDC says its data can’t clarify that num-
ber, but that such information is irrelevant
at the moment, because scientists can’t
evaluate the health consequences of such
complex mixtures.
But that and other missing information
needs to be developed as soon as possible, says
Matthew Cahillane, an environmental health
specialist with the New Hampshire Depart-
ment of Health and Human Services. At the
moment, “we’re basically firefighters,” he says.
“We’re playing catch-up all the time.”
What’s in There?
With the advent of U.S. environmental
programs in the 1970s, the first efforts to
gauge the impacts of toxic substances on
people focused on measuring them indi-
rectly—in the environment—in part be-
cause that was more technically feasible.
But those methods, while a key element in
understanding the overall exposure picture,
provide only rough parameters. They can’t
track what actually gets into people through
all the potential pathways—such as inhala-
tion, ingestion, or dermal absorption—and
can’t evaluate what stays in. Plus, the
amount of any one chemical detected in a
biomonitoring sample presents only a snap-
shot taken at one point in time. The expo-
sure reflected may be recent or old, chronic
or isolated. A single biomonitoring event is
insufficient for understanding the magni-
tude, frequency, or duration of exposure, or
the absorption, distribution, metabolism,
or excretion of a substance.
With those limitations in mind, some
researchers began to probe what was actu-
ally in people. One of the earliest efforts
began in 1976 with studies of lead. The
findings of worrisome concentrations in
many people eventually led to campaigns
to remove lead from gasoline and paint. In
response to public concerns about pollu-
tion that built in the 1980s and 1990s, the
National Academies’ National Research
Council recommended in 1991 that the
country should create a national program
to track chemicals in human tissues. That
helped lead to the adoption and expansion
of several efforts. In 1993, the EPA began
its National Human Exposure Assessment
Survey, which assessed 46 chemicals in
460 participants in 3 U.S. regions. The
results have yet to be fully analyzed, but
have been evaluated for some associations
between levels of environmental exposure
and biomarkers.
Many other independent studies,
including those performed by companies
investigating their own chemicals, have pro-
vided clues about various substances. But
these studies often focus on occupational
exposures to specific chemicals under spe-
cific conditions, and thus do not apply
when estimating background exposures for
the general U.S. population. Furthermore,
numerous barriers, such as funding limita-
tions, variations in study methodologies
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and data systems, and lack of coordination
between government agencies, have stymied
the development of any extensive informa-
tion, the U.S. General Accounting Office
concluded in its May 2000 report Toxic
Chemicals: Long-Term Coordinated Strategy
Needed to Measure Exposures in Humans.
The first substantial breach in that grid-
lock came 21 March 2001, when the CDC
released its first National Report on Human
Exposure to Environmental Chemicals. That
report covered 27 substances, including
lead and 12 other metals, 6 pesticide
metabolites, the nicotine metabolite coti-
nine, and 7 metabolites of phthalates, a
class of chemicals used in products such as
fragrances, industrial solvents, and flexible
plastic products. For that study, researchers
evaluated blood and urine samples from
about 3,800 representative volunteers who
participated in the 1999 NHANES.
On 31 January 2003, the CDC unveiled
its  Second National Report. The CDC
expects the report to be used in a number of
ways. One of the primary uses will be to
determine what substances people are
exposed to, at what concentrations, and
whether those concentrations are toxic. For
the few substances that do have established
toxicity thresholds, such as lead, it will also
help determine how many people may have
unsafe levels. 
As the database grows, it will provide
increasingly reliable information on what
the typical concentration ranges are for
various population groups, providing
physicians and public health officials with
valuable perspective on what is “normal” in
the United States. It can also provide key
information on the success or failure of
intervention programs, such as antismok-
ing initiatives, lead control programs, and
bans and other efforts aimed at reducing
pesticide body burden.
Most Extensive Assessment So Far
The new report offers a greatly expanded
body of information, including both old and
new data on the initial 27 substances and
new data on 89 other substances or their
metabolites, including dioxins, furans, poly-
chlorinated biphenyls (PCBs), polycyclic
aromatic hydrocarbons, plant estrogens, and
an expanded list of pesticides. With the
additional data available, based on blood
and urine samples drawn in 1999 and 2000
from about 1,700–8,000 people per sub-
stance, the CDC has been able to provide
the first breakdowns by age, sex, and race/
ethnicity. “It’s a giant step forward,” says
JimP irkle, deputy director for science at the
Environmental Health Laboratory.
To  find out more about the potential
adverse health impacts of the substances
found in the CDC study, researchers will be
scrutinizing the findings for years to come.
Some of their focus will be on the variations
in exposure by demographic strata that
popped up in the CDC study. 
For instance, urine concentration of
barium, which occurs naturally and is used
in products such as paint, rubber, and
ceramics, was about 65% higher in children
aged 6–11 than in people 20 and older, and
was nearly twice as high in non-Hispanic
whites as in Mexican Americans. For the
naturally occurring plant estrogen genis-
tein, found primarily in foods such as soy-
beans, Mexican Americans have a mean
urine concentration about 65% higher than
non-Hispanic blacks. Although associated
with health benefits including lowering the
risk of osteoporosis and some cancers, phy-
toestrogens such as genistein also are sus-
pected of reducing reproductive capacity
and promoting other cancers.
Mercury concentrations in blood were
about three times higher in females aged
16–49 than in children aged 1–5, and were
more than 40% higher in non-Hispanic
blacks than in non-Hispanic whites or
Mexican Americans. About 8% of women of
reproductive age had mercury levels over the
EPA’s reference dose for organic mercury.
The health effects of mercury depend on
whether it is a metallic, organic, or inorganic
form, and on the timing, route, amount, and
length of exposure. Fetuses exposed to organ-
ic mercury may experience damage to neuro-
logical systems, and adults exposed long-term
can suffer neurological, pulmonary, and gas-
trointestinal damage. Kristina Thayer, a sen-
ior scientist with the Environmental
Working Group, an environmental organiza-
tion, suspects that something as simple as
higher consumption of canned tuna—a
known source of mercury—may play a part.
Mercury also comes from sources such as
coal-fired power plants (whose emissions can
travel many miles), medical devices, dental
amalgams, and cosmetics.
Lead concentrations were still high in
some people, but the mean concentration
in blood samples of children aged 1–5 was
about 17% lower than the mean concentra-
tion detected in NHANES III in the early
1990s. Males in the latest study had 47%
higher concentrations than females.
Chemicals in the same class can be
absorbed, metabolized, and excreted by
Focus | Body of Evidence
Is It Enough to Avoid Exposures?
A pilot study by the Mount Sinai School of Medicine, in collaboration with two
environmental organizations, the Environmental Working Group and
Commonweal, revealed that nine volunteers had an average of 91 toxic sub-
stances in their bodies. Out of 210 substances tested—which included polychlo-
rinated biphenyls, metals, phthalates, pesticides, and volatile substances—167
showed up in at least one person, the groups said with the release of their
report on 30 January 2003. Each test subject had a total of anywhere from 77 to
106 substances in his or her blood or urine. On average, participants had 53 car-
cinogens, 58 known endocrine disruptors, 53 chemicals that are toxic to the
immune system, and 55 that are linked to birth defects or abnormal develop-
ment. The health effects of chemical combinations, or even single substances,
remain poorly understood, however.
The study is not peer-reviewed, and, due to the small sample size, the results
don’t reflect what might be found in the U.S. population. But Kristina Thayer, a
senior scientist with the Environmental Working Group, is concerned by the
results, in part because the nine volunteers—who included environmental
health activists, health care professionals, and a journalist familiar with environ-
mental health issues—likely lead “less toxic” lives than many people. “Our folks
are pretty savvy and know what to avoid, but it wasn’t good enough,” she says.
“Even when you try to avoid exposure, you can’t.”
U.S. residents shouldn’t have to be so savvy, says one critic of U.S. toxic sub-
stance policies. “This study merely confirms what we’ve known for a long time,”
says Samuel Epstein, a professor emeritus of environmental and occupational
medicine at the University of Illinois School of Public Health in Chicago and
chairman of the Cancer Prevention Coalition—that a wide range of toxic sub-
stances are getting into people. He has followed similar studies for decades, and
says that government agencies should have taken more aggressive action years
ago to slash exposures to toxic substances. –Bob Weinholdpeople in very different ways. Mono-ethyl
phthalate, created in the body from diethyl
phthalate, was present in the urine of adults
aged 20 and older at nearly twice the con-
centration found in children aged 6–11.
Diethyl phthalate is used in products such
as fragrances, soaps, and hand lotions. In
contrast, mono-benzyl phthalate, created in
the body from benzylbutyl phthalate, was
present in the urine of children aged 6–11
at a concentration more than three times
higher than that found in people aged 20
and older. Benzylbutyl phthalate is used in
products such as adhesives, sealants, and car
care products.
Along with the differences in age, sex,
and race/ethnicity, there were some large
differences in concentrations between the
upper and lower percentiles. In the case of
2,5-dichlorophenol, a urine metabolite of
p-dichlorobenzene, which is used in prod-
ucts such as insect repellents and deodoriz-
ers, concentrations in the 95th percentile
were  about 230 times higher than those
found in the 25th percentile. And with
several of the plant estrogens, the differ-
ences between the 95th and 10th per-
centiles ranged from 100-fold to nearly
200-fold. 
Does Exposure Cause Health
Problems?
Large variations between percentiles can be
caused for three reasons, says George
Lucier, an advisor to the National Toxi-
cology Program. First, people are exposed
to varying amounts of different chemicals.
Second, some chemicals are rapidly
degraded by the body, and the time
between exposure and sampling is critical
to attaining comparable measures. Third,
different people degrade chemicals at dif-
ferent rates for reasons related to age, sex,
genetics, and diet.
The large differences in the CDC
report raised a red flag for Thayer, who
noted that the few toxic substances that do
have health standards typically have only a
10-fold safety margin built into them as a
hedge against variations in human vulner-
ability and uncertainties in regulatory
assumptions. Current hedge factors may
not address the ranges of exposure found
in the CDC report, she observes, and
should be addressed in future investiga-
tions and regulations.
Very  little is known about the health
effects that might be caused by the concen-
trations found in the test subjects in the
CDC study, or from the combined effects of
these substances. Some industry representa-
tives suggest there may not be much to
worry about. “It hasn’t been determined
that reducing exposure would result in
improved health,” says Jennifer Bian-
caniello, a spokeswoman for the American
Chemistry Council. 
Among the studies of potentially toxic
substances that have been conducted, some
are showing adverse health effects at what
are considered low doses. For instance,
monoethyl phthalate, at concentrations
present in our environment, causes DNA
damage in sperm, reported Susan Duty of
the Harvard School of Public Health and
colleagues in December 2002 in EHP
online. The EPA has established a peer-
review panel to assess the so-called low-dose
hypothesis, which holds that endocrine-dis-
rupting chemicals cause adverse health
effects at extremely low doses. In a 26
March 2002 statement on the findings of
the panel, the agency said the panel found
that “there were credible studies supporting
a low-dose effect, but that the effects were
‘. . . dependent on the compounds studied
and the endpoint measured.’” The panel
also identified credible studies that did not
support a low-dose effect.
Given all the complex interactions that
studies suggest can occur with exposure to
toxic substances and other stressors, and
given the role of other poorly understood
factors such as the avenues and timing of
human exposure, information on sub-
stances in people alone isn’t a magic bullet.
“[The  Second National Report] is just a
snapshot in the middle of the biological
story,” Gilman cautions.
Using the Results
Nonetheless, human exposure data are an
important part of the bigger picture. For
instance, they likely will help shape the
work of one of the developing research
tools—the Environmental Genome
Project—when actual testing of yet-unde-
termined substances is ready to begin in the
next five years or so, says Raymond
Tennant, director of the National Center
for Toxicogenomics. Any methods adopted
may be useful for examining human body
burdens in relation to people who are at
increased risk due to genetic predisposition.
Agencies and organizations tracking
chronic diseases also are following the
release of human exposure data with great
interest, and the CDC report will improve
scientists’ ability to design more sensitive
epidemiologic studies, Lucier says. One
likely topic will be chronic diseases such as
cancer, asthma, and diabetes. Such diseases
play a part in 7 of every 10 U.S. deaths
each year, cause major limitations in activi-
ty for 25 million Americans, and affect a
total of about 90 million Americans to
some degree, according to the CDC
National Center for Chronic Disease and
Health Promotion. Many chronic diseases
have suspected environmental links. Laura
Segal, director of communications for the
Trust for America’s Health, a Washington,
D.C.–based advocacy organization, says
the report will “give us a fighting chance
against chronic diseases” by providing some
of the first data regarding potential linkages
with toxic substances.
The data are already shaping some
research efforts. Cahillane says that New
Hampshire was going to investigate radon
as part of its work with the CDC’s chronic
disease studies, but has decided after
reviewing the Second National Report that
mercury is a better research topic. 
To  help expand the limited national
data on chronic diseases, the CDC received
its first funding in 2002 for a national envi-
ronmental public health tracking network.
But it will be many years before the accu-
mulating data on diseases and toxic sub-
stances in people and the environment will
be meshed. “Each of these huge mountains
of data have to be made much more order-
ly and understandable,” says Richard J.
Jackson, director of the CDC National
Center for Environmental Health.
Despite much missing information,
public health officials have already begun
to use the CDC data to assess environmen-
tal health issues. In their study of the
unusually high number of acute lympho-
cytic leukemia cases in Fallon, Nevada
(where suspected exposures include agricul-
tural, military, mining, and naturally
occurring pollutants), the CDC and the
Agency for Toxic Substances and Disease
Registry (ATSDR) used the Second
National Report to put their local data in
context. They found that tungsten concen-
trations in Fallon residents were far higher
than the national mean cited in the report,
and also found slight elevatations in con-
centrations of antimony, barium, cesium,
cobalt, molybdenum, uranium, and 7 pes-
ticides, as well as detectable concentrations
of 18 PCBs. However, the agencies are say-
ing so far that there is no proof that such
exposures led to the leukemia increase,
although some research continues. 
Community activists in Anniston,
Alabama, home to extensive PCB pollu-
tion, are comparing the CDC’s data on
substances such as PCBs to their own data,
and say they are confirming their suspicions
that their residents are being exposed to
high levels of pollutants. “We have resi-
dents with godawful numbers that are a lot
higher than what [the CDC] found,” says
Shirley Baker, a health consultant to
Anniston’s Community Against Pollution
organization. She adds that the community
group likely will use the CDC data in its
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requests for grants and other funding, and
in litigation. The ATSDR is developing a
proposal for a multiyear, multimillion-
dollar study of Anniston, and will use the
Second National Report to help put its find-
ings in context, says John Abraham, chief of
the ATSDR’s Exposure Investigations and
Consultations Branch in the Health
Assessment and Consultation Division.
Industry groups, too, are already using
the CDC studies. “They do inform our
industry on better ways to do things,” says
Angelina Duggan, director of science poli-
cy for CropLife America, a pesticide indus-
try organization.
Now What?
The CDC plans to keep building its data-
base and report the results every two years.
The Second National Report cost $6.5 mil-
lion in direct laboratory expenses, with
other expenses included in the $25 million
that NHANES spends each year for its
overall study. The next exposure study
should also cost about $6.5 million, which
already has been committed, Osterloh says. 
Blood and urine samples for the next
report, covering 2001 and 2002, have
already been drawn from volunteers, fol-
lowing protocols similar to the two earlier
studies. Samples from sources in the body
other than blood and urine—such as fat or
bone—likely would reveal additional body
burden information, but have not been
taken because they require more invasive
techniques.
The number of substances that will be
analyzed will expand, and may include
about 30 volatile organic compounds
(including some chlorination by-products),
arsenic, bisphenol A, polybrominated
diphenyl ethers, perchloroethylene, and a
number of other substances. 
Lynn Goldman, a professor of occupa-
tional and environmental health in the
Johns Hopkins Bloomberg School of
Public Health, appreciates the data that are
available, but is looking forward to even
better information. “Some of the things
I’m most interested in are yet to come,” she
says. For instance, body burden data for
children aged 5 and under would be very
helpful in her work as a pediatrician.
However, that information will be difficult
to obtain with the present testing methods,
she and the CDC acknowledge, because
blood and urine samples from small chil-
dren often aren’t large enough to do exten-
sive testing.
Researchers at the CDC are tweaking
the analytical techniques within the three
general methods they already use: isotope
dilution mass spectrometry, inductively
coupled plasma mass spectrometry, and
graphite furnace atomic absorption spec-
trometry. One benefit to this tweaking will
be lower limits of detection for many sub-
stances. For the next report, “some of the
detection limits would improve dramati-
cally,” says Osterloh. 
Jackson hopes to be able to transfer
these continually refined methods to other
laboratories around the country, because
such capabilities are rare right now. He
would also like to see the data broken out
geographically in the future. “At some
point, we hope to provide state-by-state
data,” he says. He cautions that in order to
acquire enough data, such an effort would
take a substantial investment by individual
states. Some states, however, have already
expressed interest in the idea.
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